¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)
Global Substance Abuse Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
¾à¹° ³²¿ë Ä¡·á ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023-2030³âÀÇ Á¶»ç ±â°£ µ¿¾È 10.67%ÀÇ CAGR·Î 2022³â 118¾ï 9,000¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â ¾à 267¾ï 6,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
¾à¹° ³²¿ë Ä¡·á´Â ¾à¹°À̳ª ¾ËÄÚ¿Ã ÀÇÁ¸À» ±Øº¹Çϱâ À§ÇØ ½ÃÇàµÇ´Â ´Ù¾çÇÑ °³ÀÔ°ú Ä¡·á¸¦ ¸»ÇÕ´Ï´Ù. ¾à¹° ³²¿ë Ä¡·á¿¡´Â Çൿ ¿ä¹ý, ¾à¹° º¸Á¶ ¿ä¹ý, Áö¿ø ±×·ì µî ´Ù¾çÇÑ Á¢±Ù ¹æ½ÄÀÌ ÀÖ½À´Ï´Ù. Çൿġ·á´Â ¾à¹°À̳ª ¾ËÄÚ¿Ã »ç¿ë°ú °ü·ÃµÈ °³ÀÎÀÇ Åµµ¿Í ÇൿÀ» ¼öÁ¤ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á´Â °³ÀÎ ¶Ç´Â ±×·ìÀ¸·Î ÀÌ·ç¾îÁö¸ç, ÀÎÁöÇൿġ·á, µ¿±âºÎ¿© ÀÎÅͺä, ¿ì¹ßÀû °ü¸® µîÀÌ Æ÷ÇԵ˴ϴÙ. ¾à¹°Ä¡·á´Â Áßµ¶¿¡ µû¸¥ ¿å±¸¿Í ±Ý´ÜÁõ»óÀ» ÁÙÀ̱â À§ÇØ ¸ÞŸµ·, ºÎÇÁ·¹³ë¸£ÇÉ, ³ªÆ®·º¼Õ°ú °°Àº ¾à¹°À» »ç¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº Çൿġ·á¿Í ÇÔ²² »ç¿ëµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.
½ÃÀå ¿ªÇÐ :
¿ÀÇÇ¿ÀÀ̵å Áßµ¶À» Æ÷ÇÔÇÑ ¾à¹° ³²¿ë Àå¾ÖÀÇ À¯º´·ü Áõ°¡´Â ¾à¹° ³²¿ë Ä¡·á ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. °¢±¹ Á¤ºÎ´Â ¿ÀÇÇ¿ÀÀ̵å È®»ê¿¡ ´ëÀÀÇÏ°í ¾à¹° ³²¿ë Ä¡·á ¼ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̱â À§ÇØ ´Ù¾çÇÑ Á¤Ã¥°ú ÀÌ´Ï¼ÅÆ¼ºê¸¦ ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼´Â ¾à¹°³²¿ë ¹× Á¤½Åº¸°Ç¼ºñ½º±¹(SAMHSA)ÀÌ ¾à¹°³²¿ë Ä¡·á ÇÁ·Î±×·¥¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¾à¹° ³²¿ë Ä¡·á¸¦ À§ÇÑ »õ·Î¿î ¾à¹°°ú Ä¡·á¹ý °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ºÎÇÁ·¹³îÇÉ, ³ªÆ®·º¼Õ°ú °°Àº ¾à¹°Àº ¿ÀÇÇ¿ÀÀ̵å Áßµ¶ Ä¡·á¿¡ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç, ÀÎÁöÇൿġ·á, µ¿±âºÎ¿© ¸éÁ¢°ú °°Àº Çൿġ·áµµ È¿°úÀûÀÔ´Ï´Ù. ¾à¹°³²¿ëÀå¾Ö´Â Ä¡·á°¡ ÇÊ¿äÇÑ ÀÇÇÐÀû ÁúȯÀ̶ó´Â Àνİú ¼ö¿ëÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ä¡·á¸¦ ¹Þ´Â °Í¿¡ ´ëÇÑ Æí°ßÀÌ ÁÙ¾îµé¸é¼ ¾à¹°³²¿ë Ä¡·á ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á÷ÀåÀ̳ª Çб³¸¦ ´Ù´Ï¸é¼ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ´Â ¿Ü·¡ ¾à¹°³²¿ë Ä¡·á ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿Ü·¡ Ä¡·á ÇÁ·Î±×·¥ °³¹ß ¹× Ä¡·á Á¢±Ù¼º Çâ»óÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù.
ÀÌ Á¶»ç º¸°í¼´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾à¹° ³²¿ë Ä¡·á »ê¾÷ÀÇ ¼ºÀå°ú Ãß¼¼´ÂÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
½ÃÀå ¼¼ºÐÈ :
¾à¹° ³²¿ë Ä¡·á ½ÃÀå º¸°í¼ÀÇ ÀÌ ¼½¼Ç¿¡¼´Â ±¹°¡ ¹× Áö¿ªº° ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·« ´ã´çÀÚ°¡ °¢ Á¦Ç° ¶Ç´Â ¼ºñ½ºÀÇ ´ë»ó °í°´À» ½Äº°Çϰí ÇâÈÄ ºñÁî´Ï½º ±âȸ¸¦ ÆÄ¾ÇÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.
Ä¡·á À¯Çüº°
- ´ã¹è/´ÏÄÚÆ¾/ÀüÀÚ´ã¹è
- ¾ËÄÚ¿Ã
- ¸¶¸®È³ª
- ÇÕ¼º Ä«³ªºñ³ëÀ̵å
- ó¹æ¾à ¹× ÀϹÝÀǾàǰ
- ±âŸ
¿ëµµº°
- º´¿ø
- Áø·á¼Ò
- ÀçȰ¼¾ÅÍ
- ±âŸ
Áö¿ªº° ºÐ¼®
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì ¿¬¶ô ºÎʵ右´Ï´Ù. ´ç»çÀÇ Á¶»ç ÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå ÁÖ¿ä ¿ä¾à
- ½ÃÀå ÇÏÀ̶óÀÌÆ®
- ¼¼°è ½ÃÀå ÇöȲ
Á¦3Àå ¾à¹° ³²¿ë Ä¡·á - »ê¾÷ ºÐ¼®
- ¼·Ð : ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- ¾÷°è µ¿Çâ
- PorterÀÇ Five Forces ºÐ¼®
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®
- ¹ë·ùüÀÎ ºÐ¼®
- ¿øÀç·á ºÐ¼®
- ¿øÀç·á ¸®½ºÆ®
- ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
- ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
- ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
- ¸¶ÄÉÆÃ Ã¤³Î
- Á÷Á¢ ¸¶ÄÉÆÃ
- °£Á¢ ¸¶ÄÉÆÃ
- ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ
Á¦5Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°
- Ä¡·á À¯Çüº° °³¿ä
- ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
- Ä¡·á À¯Çüº° ºÐ¼®
- ´ã¹è/´ÏÄÚÆ¾/ÀüÀÚ´ã¹è
- ¾ËÄÚ¿Ã
- ¸¶¸®È³ª
- ÇÕ¼º Ä«³ªºñ³ëÀ̵å(Cannabinoids)
- ó¹æ¾à ¹× ÀϹÝÀǾàǰ
- ±âŸ
Á¦6Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
- ÃÖÁ¾ ¿ëµµº° °³¿ä
- ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
- ÃÖÁ¾ ¿ëµµº° ºÐ¼®
- º´¿ø
- Áø·á¼Ò
- ÀçȰġ·á¼¾ÅÍ
- ±âŸ
Á¦7Àå ¼¼°èÀÇ ¾à¹° ³²¿ë Ä¡·á ½ÃÀå ºÐ¼® : Áö¿ªº°
- Áö¿ªº° Àü¸Á
- ¼·Ð
- ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø
- ºÏ¹Ì : ºÎ¹®º°
- ºÏ¹Ì : ±¹°¡º°
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø
- À¯·´ : ºÎ¹®º°
- À¯·´ : ±¹°¡º°
- ¿µ±¹
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- È£ÁÖ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø
- ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
- ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Æä·ç
- Ä¥·¹
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- À̽º¶ó¿¤
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦8Àå ¾à¹° ³²¿ë Ä¡·á ±â¾÷ÀÇ °æÀï ±¸µµ
- ¾à¹° ³²¿ë Ä¡·á ½ÃÀå °æÀï
- Á¦ÈÞ/Çù·Â/ÇÕÀÇ
- ÀμöÇÕº´(M&A)
- ½ÅÁ¦Ç° ¹ß¸Å
- ±âŸ °³¹ß
Á¦9Àå ±â¾÷ °³¿ä
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
- ½ÃÀå ÁýÁßµµ
- Teva Pharmaceutical Industries Ltd.
- Abbott
- GSK plc.
- Cipla Inc.
- Lilly(Eli Lilly and Company)
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Viatris Inc.
- AstraZeneca
Âü°í - ±â¾÷ ÇÁ·ÎÆÄÀϸµ¿¡¼ À繫 ¼¼ºÎ Á¤º¸ ¹× ÃÖ±Ù °³¹ß ÇöȲÀº ÀÌ¿ë °¡´É ¿©ºÎ¿¡ µû¶ó ´Þ¶óÁö°Å³ª ºñ°ø°³ ȸ»çÀÇ °æ¿ì ´Ù·çÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.
LSH
The global demand for Substance Abuse Treatment Market is presumed to reach the market size of nearly USD 26.76 BN by 2030 from USD 11.89 BN in 2022 with a CAGR of 10.67% under the study period 2023 - 2030.
Substance abuse treatment refers to a range of interventions and therapies that are used to help individuals overcome addiction to drugs or alcohol. Substance abuse treatment can involve different approaches, including behavioral therapies, medication-assisted treatment, and support groups. Behavioral therapies involve helping individuals to modify their attitudes and behaviors related to drug or alcohol use. These therapies can be delivered in individual or group settings and may include cognitive-behavioral therapy, motivational interviewing, and contingency management. Medication-assisted treatment involves the use of medications such as methadone, buprenorphine, and naltrexone to reduce cravings and withdrawal symptoms associated with addiction. These medications are often used in conjunction with behavioral therapies.
Market Dynamics:
The increasing prevalence of substance abuse disorders, including opioid addiction, is driving the demand for substance abuse treatment services. Governments are implementing policies and initiatives to address the opioid epidemic and increase access to substance abuse treatment services. The Substance Abuse and Mental Health Services Administration (SAMHSA) in the United States provides funding for substance abuse treatment programs. There have been advancements in the development of new medications and therapies for substance abuse treatment. Medications such as buprenorphine and naltrexone have been shown to be effective in treating opioid addiction, while behavioral therapies such as cognitive-behavioral therapy and motivational interviewing have also been effective. There is increasing awareness and acceptance of substance abuse disorders as a medical condition that requires treatment. This has reduced the stigma associated with seeking treatment and increased the demand for substance abuse treatment services. There is a growing demand for outpatient substance abuse treatment services, which allow individuals to receive treatment while continuing to work or attend school leading to the development of more outpatient treatment programs and increased access to care.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of substance abuse treatment. The growth and trends of substance abuse treatment industry provide a holistic approach to this study.
Market Segmentation:
This section of the substance abuse treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Treatment Type
- Tobacco/Nicotine And Vaping
- Alcohol
- Marijuana
- Synthetic Cannabinoids
- Prescription And Over-The-Counter Medications
- Others
By End-Use
- Hospitals
- Clinics
- Rehabilitation Centers
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Substance Abuse Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the substance abuse treatment market include Teva Pharmaceutical Industries Ltd., Abbott, GSK plc., Cipla Inc., Lilly (Eli Lilly and Company), Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Viatris Inc., AstraZeneca. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . SUBSTANCE ABUSE TREATMENT - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Type
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . GLOBAL SUBSTANCE ABUSE TREATMENT MARKET ANALYSIS BY TREATMENT TYPE
- 5.1 Overview by Treatment Type
- 5.2 Historical and Forecast Data
- 5.3 Analysis by Treatment Type
- 5.4 Tobacco/Nicotine And Vaping Historic and Forecast Sales by Regions
- 5.5 Alcohol Historic and Forecast Sales by Regions
- 5.6 Marijuana Historic and Forecast Sales by Regions
- 5.7 Synthetic Cannabinoids Historic and Forecast Sales by Regions
- 5.8 Prescription And Over-the-counter Medications Historic and Forecast Sales by Regions
- 5.9 Others Historic and Forecast Sales by Regions
6 . GLOBAL SUBSTANCE ABUSE TREATMENT MARKET ANALYSIS BY END-USE
- 6.1 Overview by End-use
- 6.2 Historical and Forecast Data
- 6.3 Analysis by End-use
- 6.4 Hospitals Historic and Forecast Sales by Regions
- 6.5 Clinics Historic and Forecast Sales by Regions
- 6.6 Rehabilitation Centers Historic and Forecast Sales by Regions
- 6.7 Others Historic and Forecast Sales by Regions
7 . GLOBAL SUBSTANCE ABUSE TREATMENT MARKET ANALYSIS BY GEOGRAPHY
- 7.1. Regional Outlook
- 7.2. Introduction
- 7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
- 7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
- 7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
- 7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
- 7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis
8 . COMPETITIVE LANDSCAPE OF THE SUBSTANCE ABUSE TREATMENT COMPANIES
- 8.1. Substance Abuse Treatment Market Competition
- 8.2. Partnership/Collaboration/Agreement
- 8.3. Merger And Acquisitions
- 8.4. New Product Launch
- 8.5. Other Developments
9 . COMPANY PROFILES OF SUBSTANCE ABUSE TREATMENT INDUSTRY
- 9.1. Top Companies Market Share Analysis
- 9.2. Market Concentration Rate
- 9.3. Teva Pharmaceutical Industries Ltd.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
- 9.4. Abbott
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
- 9.5. GSK plc.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
- 9.6. Cipla Inc.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
- 9.7. Lilly (Eli Lilly and Company)
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
- 9.8. Novartis AG
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
- 9.9. Sun Pharmaceutical Industries Ltd.
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
- 9.10. Dr. Reddy's Laboratories Ltd.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
- 9.11. Viatris Inc.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
- 9.12. AstraZeneca
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies